罗格列酮对2型糖尿病病人血糖、血压、血脂的影响

目的 :评价罗格列酮的降糖作用及对血压、血脂、血胰岛素的影响。方法 :5 9例 2型糖尿病病人 ,均为男性 ,分治疗组 30例 ,年龄 (6 8±s 10 )a ,对照组 2 9例 ,年龄 (6 6± 10 )a。在原治疗基础上 ,治疗组加服罗格列酮 ,对照组加服二甲双胍 ,疗程均为16wk。观察 2组治疗前后血糖、血压、血脂及血胰岛素水平的变化。结果 :治疗后 ,2组血糖及糖化血红蛋白水平均下降 (P <0 .0 1)。胰岛素敏感性均有改善 ,治疗组优于对照组 (P <0 .0 1)。治疗组高密度脂蛋白胆固醇升高 (0 .1± 0 .3)mmol·L- 1,P <0 .0 5 ,收缩压和舒张压均降低 (P <0 .0 1,P <0 .0 5 ) ,对照组无此变化。结论 :罗格列酮有很好的降糖作用 ,并能改善胰岛素抵抗、降低血压、调节血脂 ,可能对代谢性疾病和心血管疾病有益

Effect of rosiglitazone on serum glucose,lipid and blood pressure in patients with type 2 diabetes mellitus

AIM: To evaluate the effects of rosiglitazone therapy on serum glucose, lipid, blood pressure and insulin resistance in patients with type 2 diabetes mellitus. METHODS: Fifty-nine patients with type 2 diabetes mellitus were divided into treatment group (n=30, age (68±s 10) a) and control group (n=29, age (66±10)a). All patients were male. Based on original treatment, rosiglitazone was administrated in the treatment group and metformin for the control group. The period of treatment was 16 wk for each of both groups. The levels of serum glucose, lipid, insulin and blood pressure were measured before and after the treatment. RESULTS: After treatment, the levels of blood glucose and glycosylated hemoglobin were both decreased (P<0.01). The insulin resistance was improved in both groups, but rosiglitazone group was superior to metformin's (P<0.01). In treatment group, the high density lopoprotein cholesterol increased (0.1±0.3) mmol·L~(-1) ((P<0.05)) and the blood pressure decreased. CONCLUSION: Rosiglitazone is effective in decreasing serum glucose and blood pressure, improving insulin sensitivity and down regulating blood lipid. It may be has potential benefit for metabolic and cardiovascular diseases.